Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?

ABSTRACT:

SUBMITTER: Lieberman HB 

PROVIDER: S-EPMC8798247 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature